Jefferies Financial Group Inc. boosted its holdings in Zoetis Inc. (NYSE:ZTS – Free Report) by 35.0% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 25,000 shares of the company’s stock after buying an additional 6,475 shares during the period. Jefferies Financial Group Inc.’s holdings in Zoetis were worth $1,746,000 at the end of the most recent reporting period.
Several other hedge funds have also recently bought and sold shares of the business. Wealthfront Advisers LLC raised its holdings in shares of Zoetis by 80.2% during the 2nd quarter. Wealthfront Advisers LLC now owns 76,113 shares of the company’s stock valued at $5,469,000 after buying an additional 33,873 shares during the period. Pacer Advisors Inc. boosted its position in Zoetis by 16.7% during the 1st quarter. Pacer Advisors Inc. now owns 165,570 shares of the company’s stock valued at $19,572,000 after purchasing an additional 23,687 shares during the period. Diamond Hill Capital Management LLC Investment Advisor grew its position in Zoetis by 21.5% in the 2nd quarter. Diamond Hill Capital Management LLC Investment Advisor now owns 3,557,436 shares of the company’s stock worth $255,637,000 after purchasing an additional 629,974 shares during the last quarter. Nykredit A S bought a new stake in shares of Zoetis during the second quarter valued at about $10,042,000. Finally, Flossbach Von Storch SE acquired a new stake in Zoetis in the second quarter worth approximately $302,601,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.
Zoetis Stock Performance
ZTS stock opened at $83.65 on Monday. The company has a debt-to-equity ratio of 2.51, a quick ratio of 1.40 and a current ratio of 2.35. The stock has a market cap of $33.99 billion, a P/E ratio of 14.23, a P/E/G ratio of 1.21 and a beta of 0.67. The firm has a 50 day simple moving average of $76.28 and a 200 day simple moving average of $91.56. Zoetis Inc. has a 52 week low of $68.77 and a 52 week high of $132.49.
Zoetis (NYSE:ZTS – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported $1.75 EPS for the quarter, beating analysts’ consensus estimates of $1.51 by $0.24. The firm had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 26.15% and a return on equity of 85.90%. The firm’s revenue was down 1.3% on a year-over-year basis. During the same period in the previous year, the firm posted $1.70 earnings per share. Research analysts anticipate that Zoetis Inc. will post 6.29 earnings per share for the current fiscal year.
Zoetis Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 1st. Stockholders of record on Friday, October 30th will be issued a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 2.5%. The ex-dividend date is Friday, October 30th. Zoetis’s payout ratio is currently 36.05%.
Analysts Set New Price Targets
Several research analysts have issued reports on ZTS shares. Citigroup dropped their price target on Zoetis from $112.00 to $96.00 and set a “buy” rating on the stock in a report on Tuesday, August 11th. The Goldman Sachs Group initiated coverage on shares of Zoetis in a research report on Friday, October 16th. They issued a “neutral” rating and a $74.00 price target for the company. BTIG Research dropped coverage on shares of Zoetis in a research note on Friday, October 30th. They issued a “buy” rating and a $200.00 price objective for the company. William Blair cut shares of Zoetis from an “outperform” rating to a “market perform” rating in a research report on Thursday, August 6th. Finally, Piper Sandler cut their target price on shares of Zoetis from $90.00 to $80.00 and set a “neutral” rating on the stock in a research note on Monday, August 10th. Eight research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $101.25.
Read Our Latest Stock Report on ZTS
About Zoetis
Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish. The company’s offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.
See Also
- Five stocks we like better than Zoetis
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
